A Pilot Investigation of the Nasal Mucosal Absorption, Retention, and Metabolism of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray When Each Formulation Is Administered to Currently Symptomatic Patients (18 Years or Older) With Documented Perennial Allergic Rhinitis (PAR).
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2013
At a glance
- Drugs Ciclesonide (Primary)
- Indications Perennial allergic rhinitis
- Focus Pharmacokinetics
- 19 Jul 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Nov 2008 New trial record.